Riskpilot← Back to searchSign inGet full accessBiogen Sweden AB
ABActiveOrg 5565644308Vasagatan 7Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199910-19 employees
Revenue 2024
SEK 584,4M
-8% vs 2023
EBITDA margin
3.7%
-4% vs 2023
Equity ratio
59.6%
Financial strength
Net profit 2024
SEK 17,4M
-2% vs 2023
| Revenue | SEK 584,4M | -8% |
| EBITDA | SEK 21,7M | -4% |
| Net profit | SEK 17,4M | -2% |
| Total assets | SEK 260M | +3% |
| Equity | SEK 154,9M | +13% |
| Employees | — | — |
Legal name
Biogen Sweden AB
Org number
5565644308
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7 januari 1999
Share capital
SEK 100 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna externa firmatecknarna
Company purpose
Bolaget har till föremål för sin verksamhet att marknadsföra och handla med läkemedel samt bedriva annan därmed förenlig verksamhet.
Address
Vasagatan 7
Phone
+46859411360
Email
infosweden@biogenidec.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 666 999 | 764 180 | 680 580 | 638 549 | 584 432 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 34 324 | 38 826 | 24 699 | 22 731 | 21 743 |
| Depreciation & amort. | −375 | −396 | −277 | −211 | −203 |
| EBIT | 33 949 | 38 430 | 24 422 | 22 520 | 21 540 |
| Net financials | −1 193 | −853 | −426 | 1 957 | 1 670 |
| Profit before tax | 28 366 | 33 557 | 21 724 | 23 110 | 22 781 |
| Tax | −6 326 | −7 217 | −4 827 | −5 390 | −5 340 |
| Net profit | 22 040 | 26 340 | 16 897 | 17 720 | 17 441 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 211 099 | 275 082 | 250 512 | 252 777 | 259 951 |
| Equity | 76 462 | 102 802 | 119 699 | 137 419 | 154 860 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 86 286 | 119 949 | 76 523 | 60 165 | 49 808 |
| Total debt | 86 286 | 119 949 | 76 523 | 60 165 | 49 808 |
EBITDA margin
3.7%
This company
15.8%
Market median
-77% vs market
20202024
Equity ratio
59.6%
This company
38.2%
Market median
+56% vs market
20202024
Return on equity
11.3%
This company
18.4%
Market median
+39% vs market
20202024
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20202024
Asset turnover
2.25×
This company
1.12×
Market median
+101% vs market
20202024
Debt / equity
0.68×
This company
0.62×
Market median
+10% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TK External Signatory | External Signatory | 2024 |
ME External Signatory | External Signatory | 2022 |
AC Chief Auditor | Chief Auditor | 2021 |
AT External Signatory | External Signatory | 2021 |
| Former (3) | ||
JF External Signatory | External Signatory | 2021 – 2022 |
JS External Signatory | External Signatory | 2021 – 2024 |
LA External Signatory | External Signatory | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Former (5) | ||
| Chairman | 2022 – 2023 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2024 – 2026 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BIOGEN NETHERLANDS B.V.
Biogen Sweden AB (this company)Board members of Biogen Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tomasz Klimczak | External Signatory | 0 companies |
| Johanna Friedl-Naderer | External Signatory | 0 companies |
| Jann Saxtorph Haagaard | External Signatory | 0 companies |
| Michael Edward Dambach | External Signatory | 0 companies |
| Leif Arne Lohm | External Signatory | 0 companies |
| Anneli Christina Richardson | Chief Auditor | 0 companies |
| Anna Therése Rudslätt Debou | External Signatory | 0 companies |
| Allan Frank Fischer Petersen | Chairman | 0 companies |
| Jan Krister Sandström | Chairman | 0 companies |
| Ulf Johan Ström | Chairman | 0 companies |
| Dennis Dewy Baars | Board of Directors | 0 companies |
| Sérgio Ferreira Da Silva Teixeira | Board of Directors | 0 companies |
| Wolfram Werner Schmidt | Board of Directors | 0 companies |
| Morten Lofthus Tangnes | Board of Directors | 0 companies |
| Jonas Fredrik Behm | Chairman | 0 companies |